Now I have all the information I need to construct the consolidated review.

## Summary

This paper proposes using synthetic data (specifically, synthetic liver tumors generated via morphological image processing on healthy CT volumes) as a validation set for model checkpoint selection in medical image segmentation. The authors demonstrate that a larger, more diverse synthetic validation set selects better model checkpoints than a small real-tumor validation set (Figs. 2-3), and that combining synthetic training (via a "continual learning" framework) with synthetic validation yields statistically significant DSC improvements on both in-domain LiTS and out-domain FLARE'23 test sets (Table 1). The paper also reports substantial gains in detecting tiny tumors (radius < 5mm), which is clinically relevant for early cancer detection.

## Strengths

1. **Synthetic validation demonstrably selects better checkpoints than a small real validation set.** Figures 2 and 3 hold the training regime constant (trained on real LiTS data) and show that the checkpoint chosen by the synthetic validation set (cohort 5, 50 CT volumes) is nearly identical to the one chosen by the test set in both in-domain and out-domain evaluations, whereas the checkpoint chosen by the small real validation set (cohort 2, 5 CT volumes) is clearly suboptimal. This directly supports the paper's central practical claim.

2. **Statistically significant performance gains from the full framework.** Table 1 reports DSC improvements with non-overlapping 95% confidence intervals: from 26.7% (22.6–30.9) to 34.5% (30.8–38.2) on the LiTS test set and from 31.1% (26.0–36.2) to 35.4% (32.1–38.7) on FLARE'23 when using synthetic training and validation versus real training and validation.

3. **Clinically meaningful improvement in tiny tumor detection.** Figure 5 shows sensitivity for tumors <5mm radius improving from ~33% to ~55% (in-domain) and ~34% to ~52% (out-domain). This is a practically important result given the scarcity of early-stage tumor examples in real datasets.

4. **Multi-dataset evaluation with both in-domain and out-domain test sets.** The study uses LiTS (internal validation), FLARE'23 (external validation, 120 CTs from >30 centers), and an assembled healthy CT dataset (CHAOS, BTCV, Pancreas-CT), which strengthens generalizability claims.

5. **In-domain synthetic validation extension (Figure 6) provides a useful additional finding.** The experiment showing that generating synthetic validation from healthy CTs in the same domain as the test set (FLARE'23 healthy cases) perfectly matches the test set's optimal checkpoint adds practical value and insight.

## Weaknesses

### Fatal
None.

### Major

1. **The synthetic validation experiment is confounded by scale and diversity, not just the synthetic/real distinction.** Figures 2-3 compare real validation (cohort 2: 5 CT volumes) against synthetic validation (cohort 5: 50 CT volumes × 3 tumors each = 150 volumes). The synthetic validation set is simultaneously larger, more diverse, and synthetic. The experimental design cannot disentangle whether the improvement comes from the *synthetic nature* of the data or simply from having a *larger and more diverse* validation set. This is the most significant threat to the paper's internal validity. The paper's practical contribution (synthetic data enables large-scale validation when real data is scarce) remains defensible, but the current experiments cannot support a claim that synthetic data is *intrinsically* better than real data of comparable size and diversity for validation.

2. **The "continual learning" framing is oversold relative to the implementation.** Section 3.1 defines domain-incremental learning per van de Ven et al. (model sequentially encounters data from different domains), but the actual implementation pools healthy CT volumes from multiple sources (CHAOS, BTCV, Pancreas-CT) without sequential domain exposure, domain boundaries, or evaluation of catastrophic forgetting. The "continual" aspect is essentially continuous generation of synthetic tumor examples on a fixed set of healthy CTs — this is better described as "dynamic synthetic training" than as continual learning. This overclaiming risks misleading readers about the nature of the contribution.

### Minor

1. **Figure 5 (early cancer detection) reports sensitivity without confidence intervals.** The main results in Table 1 include 95% CIs, so their absence for the clinically critical tiny-tumor sensitivity claims is conspicuous and weakens the quantitative rigor. The improvement from ~33% to ~55% is striking, but without uncertainty quantification, the reliability of this gain is unclear.

2. **The tumor generator lacks quantitative validation.** The paper relies on "visual inspection and feedback from medical professionals" for post-processing (Section 3.2), but provides no quantitative comparison between synthetic and real tumor characteristics (e.g., intensity distributions, shape statistics, boundary regularity). Since the entire pipeline depends on the realism of synthetic tumors, a quantitative characterization would substantially strengthen confidence in the approach.

### Trivial

1. **FLARE'23 domain shift justification is thin.** The paper's justification that FLARE'23 is "out-domain" relies solely on "different medical centers" without any quantitative measure of distribution shift. The observation that static real training achieves *higher* DSC on FLARE'23 (31.1%) than on the "in-domain" LiTS test set (26.7%) suggests the domain relationship is more nuanced than presented.

## Nice-to-Haves

- **Ablation over validation set size:** Varying the number of synthetic validation volumes (e.g., 5, 10, 25, 50) would directly address whether the synthetic nature confers advantage beyond scale, and give practitioners practical guidance.
- **Cross-validation experiment:** Training on synthetic data with real validation (or training on real data with synthetic validation) would help isolate the contribution of each component.
- **Quantitative tumor generator validation:** Adding distributional comparisons (size, intensity, shape) between synthetic and real tumors would strengthen the pipeline's credibility.
- **The "continual learning" framing could be dropped or significantly toned down** in favor of "dynamic synthetic training," which more accurately describes the method.
- Confidence intervals for the sensitivity results in Figure 5.

## Removed Points

- *Criticism that the paper's novelty is overstated / "not a conceptual contribution"* — Removed. The paper demonstrates a genuinely under-explored application of synthetic data (validation, not just training) with practical value. The contribution is legitimate even if the mechanism is straightforward.
- *Criticism that Table 1 "conflates training set changes with validation set changes" in a way that invalidates the results* — Removed as overblown. Figures 2-3 already isolate the validation effect by holding training constant. Table 1 then shows the combined framework result. The decomposition exists, though the paper could make it more explicit.
- *Claim that "the continual learning framework is misaligned with its own definition and lacks a meaningful evaluation"* — Weakened to Major (see above). The critic's broader dismissal is excessive — the paper does use multiple domains (different source datasets) and does evaluate the model on held-out test sets. The issue is that the implementation doesn't match standard continual learning protocols.

## Novel Insights

The harsh critic's observation that the paper's central comparison conflates two factors (synthetic vs. real AND small vs. large) is the most penetrating insight. This is a genuine experimental design limitation that the paper does not acknowledge. However, the paper's practical framing (synthetic data as a workaround for scarce real validation data) makes this confound less damaging than it would be for a paper claiming conceptual novelty about synthetic vs. real data. The critic's observation that the continual learning framing is misapplied is also insightful — the paper would be stronger if it dropped this framing and described the method as "dynamic synthetic training."

## Suggestions

1. **Acknowledge and bound the scale confound explicitly.** Add an experiment or ablation that varies synthetic validation set size, or add a discussion section explaining that the paper's claim is practical (synthetic data enables large-scale validation when real data is unavailable) rather than theoretical (synthetic > real at equal scale).

2. **Drop or substantially revise the "continual learning" framing.** Either implement true domain-incremental learning (sequential domain exposure with forgetting metrics) or relabel the method as "dynamic synthetic training on a stream of synthetic data."

3. **Add confidence intervals to Figure 5.** The tiny-tumor detection results are the paper's most clinically impactful claim and need proper uncertainty quantification.

4. **Add quantitative characterization of the synthetic tumor generator** (e.g., histograms of intensity values, size/shape distributions compared to real tumors from LiTS) to substantiate the claim of realism.

## Score and Decision

This paper addresses a genuine practical problem (validation set scarcity in medical imaging) and provides a reasonable workaround with supporting experiments. The main results (synthetic validation selects better checkpoints than a small real validation set; the full framework yields statistically significant gains) are supported by the data. However, the experimental design has a confound that limits internal validity, and the continual learning framing oversells what is implemented. The paper would benefit from targeted revisions but makes a useful contribution in its current form.

**Score: 5.5 / 10**

**Decision: Accept (borderline)**

MY FINAL SCORE: <score>5.5</score>
MY FINAL DECISION: <decision>Accept</decision>